Ⅱ型神经纤维瘤基因突变及表达与消化系统肿瘤

doi:10.3969/j.issn.1006-7795.2014.02.023

首都医科大学学报 ›› 2014, Vol. 35 ›› Issue (2): 257-260.doi: 10.3969/j.issn.1006-7795.2014.02.023

Ⅱ型神经纤维瘤基因突变及表达与消化系统肿瘤

张宁, 黄坚

首都医科大学附属北京友谊医院肝病中心肝硬化转化医学北京市重点实验室, 北京 100050

收稿日期:2013-10-31 出版日期:2014-04-21 发布日期:2014-04-16
基金资助:
王宝恩肝纤维化基金（20100013），教育部留学回国人员科研启动基金（2011年第41批）。

Neurofibromatosis type 2 gene mutation and its expression and tumors of digestive system

Zhang Ning, Huang Jian

Liver Research Center, Municipal Key Laboratory of Translational Medicine in Cirrhosis, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Received:2013-10-31 Online:2014-04-21 Published:2014-04-16
Contact: 黄坚 E-mail:hjlq123@yeah.net
Supported by:
This study was supported by Wang Baoen Liver Fibrosis Foundation(20100013), the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry(41 batch, 2011).

摘要/Abstract

摘要： NF2（neurofibromatosis type 2，NF2）基因是一种肿瘤抑制基因，该基因的突变可以导致2型多发性神经纤维瘤家族性肿瘤综合征的发生。近年来多项研究提示该基因突变及表达改变可能与消化系统肿瘤的发生相关。本文将对NF2基因突变及Merlin蛋白表达改变与消化系统肿瘤发生的相关性进行综述。

关键词: Ⅱ型神经纤维瘤基因, 突变, 肿瘤, 消化系统

Abstract: NF2(neurofibromatosis type 2, NF2)gene mutation is one of the hallmark of neurofibromatosis type 2 familial cancer syndrome. Recent studies have shown NF2 mutation and its expression may be associated with the pathogenesis of digestive system tumors. In this paper, we review the recent advances of NF2 gene mutation and its expression in digestive system tumors.

Key words: neurofibromatosis type 2 gene, mutation, tumor, digestive system

中图分类号:

张宁, 黄坚. Ⅱ型神经纤维瘤基因突变及表达与消化系统肿瘤[J]. 首都医科大学学报, 2014, 35(2): 257-260.

Zhang Ning, Huang Jian. Neurofibromatosis type 2 gene mutation and its expression and tumors of digestive system[J]. Journal of Capital Medical University, 2014, 35(2): 257-260.

参考文献

[1] Fukasawa T, Chong J M, Sakurai S, et al. Allelic loss of 14q and 22q, NF2 mutation, and genetic instability occur independently of c-kit mutation in gastrointestinal stromal tumor[J]. Japan J Cancer Res, 2000, 91(12):1241-1249.
[2] Pylkknen L, Sarlomo-Rikala M, Wessman M, et al. Chromosome 22q alterations and expression of the NF2 gene product, merlin, in gastrointestinal stromal tumors[J]. Hum Pathol, 2003, 34(9):872-879.
[3] Ogasawara N, Sasaki M, Ishiguro H, et al. Gastric schwannoma with adjacent external progression harbored aberrant NF2 gene[J]. Dig Endosc, 2009, 21(3):192-195.
[4] Rustgi A K, Xu L, Pinney D, et al. Neurofibromatosis 2 gene in human colorectal cancer[J]. Cancer Genet Cytogenet, 1995, 84(1):24-26.
[5] Kanai Y, Tsuda H, Oda T, et al. Analysis of the neurofibromatosis 2 gene in human breast and hepatocellular carcinomas[J]. Jpn J Clin Oncol, 1995, 25(1):1-4.
[6] Yoo N J, Park S W, Lee S H. Mutational analysis of tumour suppressor gene NF2 in common solid cancers and acute leukaemias[J]. Pathology, 2012, 44(1):29-32.
[7] Benhamouche S, Curto M, Saotome I, et al. Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver[J]. Genes Dev, 2010, 24(16):1718-1730.
[8] Evans D G, Sainio M, Baser M E. Neurofibromatosis type 2[J]. J Med Genet, 2000, 37(12):897-904.
[9] Morrow K A, Das S, Metge B J, et al. Loss of tumor suppressor Merlin in advanced breast cancer is due to post-translational regulation[J]. J Biol Chem. 2011, 286(46):40376-40385.
[10] Horiguchi A, Zheng R, Shen R, et al. Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells[J]. Prostate, 2008, 68(9):975-984.
[11] Thurneysen C, Opitz I, Kurtz S, et al. Functional inactivation of NF2/merlin in human mesothelioma[J]. Lung cancer, 2009, 64(2):140-147.
[12] Morris Z S, McClatchey A I. Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma[J]. Proc Natl Acad Sci U S A, 2009, 106(24):9767-9772.
[13] Bretscher A, Edwards K, Fehon R G. ERM proteins and merlin: integrators at the cell cortex[J]. Nat Rev Mol Cell Biol, 2002, 3(8):586-599.
[14] Gutmann D H, Giordano M J, Fishback A S, et al. Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas[J]. Neurology, 1997, 49(1):267-270.
[15] Li W, You L, Cooper J, et al. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus[J]. Cell, 2010, 140(4):477-490.
[16] Marchler-Bauer A, Lu S, Anderson J B, et al. CDD: a Conserved Domain Database for the functional annotation of proteins[J]. Nucleic Acids Res, 2011, 39(Database issue):D225-D229.
[17] Pećina-Šlaus N. Merlin, the NF2 gene product[J]. Pathol Oncol Res, 2013, 19(3):365-373.
[18] Huang J, Chen J. VprBP targets Merlin to the Roc1-Cul4A-DDB1 E3 ligase complex for degradation[J]. Oncogene, 2008, 27(29):4056-4064.
[19] Lomas J, Bello M J, Arjona D, et al. Genetic and epigenetic alteration of the NF2 gene in sporadic meningiomas[J]. Genes Chromosomes Cancer, 2005, 42(3):314-319.
[20] Ikeda T, Hashimoto S, Fukushige S, et al. Comparative genomic hybridization and mutation analyses of sporadic schwannomas[J]. J Neurooncol, 2005, 72(3):225-230.
[21] Laniewski-Wollk M, Gos M, Koziarski A, et al. Identification of mutations in the NF2 gene in Polish patients with neurofibromatosis type 2[J]. J Appl Genet, 2008, 49(3):297-300.
[22] Voltaggio L, Murray R, Lasota J, et al. Gastric schwannoma: a clinicopathologic study of 51 cases and critical review of the literature[J]. Hum Pathol, 2012, 43(5):650-659.
[23] Zhang N, Bai H, David K K, et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals[J]. Dev Cell, 2010, 19(1):27-38.
[24] Lee K P, Lee J H, Kim T S, et al. The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis[J]. Proc Natl Acad Sci U S A, 2010, 107(18):8248-8253.
[25] Xu M Z, Yao T J, Lee N P, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma[J]. Cancer, 2009, 115(19):4576-4585.
[26] Curto M, Cole B K, Lallemand D, et al. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin[J]. J Cell Biol, 2007, 177(5):893-903.
[27] Alexandrov L B, Nik-Zainal S, Wedge D C, et al. Signatures of mutational processes in human cancer[J]. Nature, 2013, 500(7463):415-421.

Ⅱ型神经纤维瘤基因突变及表达与消化系统肿瘤

Neurofibromatosis type 2 gene mutation and its expression and tumors of digestive system

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张志丽, 郭彩霞. 头颈部恶性肿瘤术后急性肺栓塞临床特点及危险因素分析[J]. 首都医科大学学报, 2022, 43(5): 787-791.
[2]	马鸣扬, 王洁玮, 李鹏. 细胞内镜评估结直肠病变的研究进展[J]. 首都医科大学学报, 2022, 43(2): 221-226.
[3]	李雪, 邢洁, 张倩, 李鹏, 吕富靖, 张澍田. 窄带成像技术联合放大内镜JES分型对早期食管癌的诊断价值[J]. 首都医科大学学报, 2022, 43(2): 210-215.
[4]	姚舒洋, 李小雪, 王淳秀, 张毅. 埃克替尼联合抗血管药物一线治疗EGFR突变晚期肺腺癌的单中心研究[J]. 首都医科大学学报, 2022, 43(2): 289-293.
[5]	孙婧, 史幼梧, 贾军, 杨颖, 孙志伟, 杜丰, 余靖, 肖艳洁, 张晓东. 血液炎症相关指标在晚期胰腺癌中的预后价值[J]. 首都医科大学学报, 2022, 43(2): 299-304.
[6]	孙灿, 邢洁, 张希, 孙秀静, 张澍田. 内镜下黏膜剥离术治疗低位直肠早癌的临床分析[J]. 首都医科大学学报, 2022, 43(1): 34-37.
[7]	陈彦, 孙英. mRNA疫苗研究进展——2021年拉斯克奖临床医学研究奖[J]. 首都医科大学学报, 2021, 42(5): 893-889.
[8]	熊枫然, 卢晶, 张英超, 谢荣荣, 赵儒轩, 李奇, 杨金奎. Kcnh6点突变单基因糖尿病家系的小鼠模型构建及表型分析[J]. 首都医科大学学报, 2021, 42(4): 575-581.
[9]	于恺英, 王晓琳, 石汉平. 肿瘤营养治疗的发展与进步[J]. 首都医科大学学报, 2021, 42(3): 499-502.
[10]	李詝, 李囡, 刘志博, 杨志. ¹⁸F-硼氨酸细胞摄取机制研究[J]. 首都医科大学学报, 2021, 42(1): 15-20.
[11]	王欣, 张俊璇, 高健, 石汉平. 免疫营养改善肿瘤患者预后[J]. 首都医科大学学报, 2020, 41(6): 1019-1024.
[12]	李兵辉. 代谢重编程的化学本质——李兵辉教授[J]. 首都医科大学学报, 2020, 41(5): 795-799.
[13]	刘军, 曹庆飞, 叶雄俊, 陈伟男, 赵海岳, 佟明, 王银银, 黄晓波, 常智杰. CREPT在肾癌组织中的表达及其与预后的关系[J]. 首都医科大学学报, 2020, 41(4): 552-557.
[14]	张闻平, 吴静, 任彦军, 常莹, 张雪娟, 马佳, 杜岚, 杨敬春. 直肠腔内超声与磁共振诊断直肠肿瘤的比较研究[J]. 首都医科大学学报, 2020, 41(4): 641-646.
[15]	孙梦雪, 王雷明, 滕梁红. 胶质瘤中BRAF基因异常的研究进展[J]. 首都医科大学学报, 2020, 41(3): 380-384.